Search Results 311-320 of 17433 for Interferon

  1. EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx - Mayo Clinic

    Interferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks prior to enrollment. Known brain metastases, unless these metastases ...

  2. Infection and Immunity: Raymund R. Razonable - Research Projects

    CMV -specific immune reconstitution after solid organ and allogeneic hematopoietic stem cell transplant. Evaluation of letermovir and maribavir to manage ...

  3. https://www.mayoclinic.org/spanish_procedure_concepts.xml

  4. Lamivudine and zidovudine (oral route) - Side effects & dosage - Mayo Clinic

    Interferon Beta-1a; Methadone; Nelfinavir; Probenecid; Rifabutin; Rifapentine; Tipranavir. Other Interactions. Certain medicines should not be used at or around ...

  5. Publications - Giovanni De Petris, M.D. - Mayo Clinic

    ... interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004 Jan 27; 77 (2):190-4. View PubMed; Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz ...

  6. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  7. Encorafenib (oral route) - Mayo Clinic

    Encorafenib is also used in combination with binimetinib to treat non-small cell lung cancer (NSCLC) that has spread in patients who have BRAF V600E mutations.

  8. AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH - Mayo Clinic

    Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents and immunomodulating agents (eg, interleukins, interferons, ...

  9. Hodgkin Clinical Trials - Mayo Clinic Research

    This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin ...

  10. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

    Treatment with systemic immunosuppressive medications (including but not limited to interferons, IL-2) within 4 weeks or 5 half-lives of the drug, whichever is ...